The Vasculitis drugs in development market research report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vasculitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vasculitis and features dormant and discontinued products.
GlobalData tracks 26 drugs in development for Vasculitis by 25 companies/universities/institutes. The top development phase for Vasculitis is preclinical with nine drugs in that stage. The Vasculitis pipeline has 25 drugs in development by companies and one by universities/ institutes. Some of the companies in the Vasculitis pipeline products market are: General Nanotherapeutics, Amgen and Pfizer.
The key targets in the Vasculitis pipeline products market include Tyrosine Protein Kinase JAK1, Tyrosine Protein Kinase JAK2, and Tyrosine Protein Phosphatase Non Receptor Type Substrate 1.
The key mechanisms of action in the Vasculitis pipeline product include Tyrosine Protein Kinase JAK1 Inhibitor with three drugs in Pre-Registration. The Vasculitis pipeline products include seven routes of administration with the top ROA being Oral and ten key molecule types in the Vasculitis pipeline products market including Small Molecule, and Monoclonal Antibody.
Vasculitis overview
Vasculitis is a term that refers to a group of diseases that cause inflammation of the blood vessels, affecting both arteries and veins. Vasculitis can have various causes, such as genetic factors, infections, immune system disorders, blood cancers, or reactions to certain drugs. Vasculitis can affect different parts of the body, such as the skin, muscles, joints, nerves, lungs, heart, digestive system, kidneys, and eyes. Depending on the type and severity of vasculitis, the symptoms and complications may vary. Some common signs of vasculitis are fever, weight loss, fatigue, headache, joint pain, skin rash, and bleeding under the skin. Vasculitis can be diagnosed by blood tests, imaging tests, or biopsy of the affected tissue. Treatment options depend on the type and cause of vasculitis, but usually involve medications to reduce inflammation and prevent flare-ups.
For a complete picture of Vasculitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
